Functional disruption of stress modulatory circuits in a model of temporal lobe epilepsy

Aynara C. Wulsin1,2, Ana Franco-Villanueva1, Christian Romancheck1, Rachel L. Morano1, Brittany L. Smith1, Benjamin A. Packard1, Steve C. Danzer2, James P. Herman1*

1 Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati School of Medicine, Cincinnati, Ohio, United States of America, 2 Department of Anesthesiology, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, United States of America

* james.herman@uc.edu

Abstract

Clinical data suggest that the neuroendocrine stress response is chronically dysregulated in a subset of patients with temporal lobe epilepsy (TLE), potentially contributing to both disease progression and the development of psychiatric comorbidities such as anxiety and depression. Whether neuroendocrine dysregulation and psychiatric comorbidities reflect direct effects of epilepsy-related pathologies, or secondary effects of disease burden particular to humans with epilepsy (i.e. social estrangement, employment changes) is not clear. Animal models provide an opportunity to dissociate these factors. Therefore, we queried whether epileptic mice would reproduce neuroendocrine and behavioral changes associated with human epilepsy. Male FVB mice were exposed to pilocarpine to induce status epilepticus (SE) and the subsequent development of spontaneous recurrent seizures. Morning baseline corticosterone levels were elevated in pilocarpine treated mice at 1, 7 and 10 weeks post-SE relative to controls. Similarly, epileptic mice had increased adrenal weight when compared to control mice. Exposure to acute restraint stress resulted in hypersecretion of corticosterone 30 min after the onset of the challenge. Anatomical analyses revealed reduced Fos expression in infralimbic and prelimbic prefrontal cortex, ventral subiculum and basal amygdala following restraint. No differences in Fos immunoreactivity were found in the paraventricular nucleus of the hypothalamus, hippocampal subfields or central amygdala. In order to assess emotional behavior, a second cohort of mice underwent a battery of behavioral tests, including sucrose preference, open field, elevated plus maze, 24h hometest monitoring and forced swim. Epileptic mice showed increased anhedonic behavior, hyperactivity and anxiety-like behaviors. Together these data demonstrate that epileptic mice develop HPA axis hyperactivity and exhibit behavioral dysfunction. Endocrine and behavioral changes are associated with impaired recruitment of forebrain circuits regulating stress inhibition and emotional reactivity. Loss of forebrain control may underlie pronounced endocrine dysfunction and comorbid psychopathologies seen in temporal lobe epilepsy.
Introduction

Temporal lobe epilepsy (TLE) is the most prevalent form of refractory epilepsy in adults, accounting for the majority of epilepsy patients requiring neurosurgery [1–3]. In some instances, TLE is preceded by an initial brain insult such as status epilepticus (SE), febrile seizures or trauma [4]. Such injuries can precipitate the development of aberrant networks in the hippocampus and other limbic structures [5,6]. Limbic network reorganization is directly implicated in the generation of seizure activity, as is evident from the efficacy of temporal lobectomy in controlling seizures [1]. In addition to its role in seizures, however, limbic reorganization may also disrupt neuroendocrine processes and emotional behaviors, contributing to the development of highly comorbid stress-related psychopathologies [7–9].

The hypothalamo-pituitary-adrenocortical (HPA) axis regulates somatic responses to both physical and emotional stress. Efficient activation and effective termination of the response is tightly regulated by negative feedback effects of glucocorticoids acting at numerous CNS loci, including the hypothalamus, prefrontal cortex, hippocampus and amygdala [10–12]. Thus, intact limbic networks are required for optimal HPA axis control. Chronic elevations in glucocorticoids are observed in a subset of patients with TLE [13], consistent with enhanced HPA axis activation and/or reduced feedback signaling. In addition, cortisol stress responses can be exaggerated in some TLE patients, and such enhanced reactivity is associated with reduced functional connectivity between the hippocampus and the frontal cortex [14]. Importantly, HPA axis hyperactivity and consequent elevations in glucocorticoids are known to remodel [15] and potentially injure [16] limbic networks while also predisposing individuals to stress-related psychopathologies [17–19]. Thus, limbic reorganization may occur at multiple levels in TLE, as a result of the initial precipitating injury, as a consequence of repeated seizure activity and following excess glucocorticoid exposure. Reorganization may result in abnormal responses to stress and increased susceptibility to aberrant emotional behaviors.

The pilocarpine-induced SE model of temporal lobe epilepsy has been extensively utilized to investigate mechanisms of epileptogenesis [3,20–22]. Additionally, we and others have shown that the initial SE leads to increased baseline secretion of glucocorticoids [23,24] that is likely to persist through the chronic epileptic period [25]. The purposes of this study are: 1) to assess the endocrine response to acute stress in the pilocarpine TLE model and 2) to determine whether epilepsy compromises the recruitment of key stress regulatory regions. Additionally, we aim to assess the validity of pilocarpine-induced SE as a model to study the complex relationship between HPA axis dysfunction and susceptibility to psychopathologies observed in human TLE.

Materials and methods

Animals

Forty 8-week-old male FVB mice (Charles River International Strain Code 207) were housed individually in standard mouse shoebox cages and acclimated to laboratory conditions for 2 weeks prior to all experimental procedures. Mice were maintained in a temperature and humidity controlled room (lights on 0500–1700) with food and water available ad libitum. All experimental procedures and protocols were conducted as approved by the University of Cincinnati Institutional Animal Care and Use Committee and in accordance with NIH guidelines for the Care and Use of Animals. Protocols were designed to limit animal stress and discomfort.

Pilocarpine protocol and experimental design

Pilocarpine is a muscarinic 1 (M1) receptor agonist that has been used extensively to induce seizures in rodents ([3] for review). High doses of pilocarpine induce a state of persistent
seizures (SE) lasting many hours, followed by the development of spontaneous seizures weeks later. For the present study, all mice were given a subcutaneous injection (s.c.) of methyl scopolamine nitrate (1 mg/kg) followed by pilocarpine (350 mg/kg, s.c.) or saline (s.c.) 15 min later. Experiments were run in two randomly-generated cohorts, each with 9–10 saline and 10–11 pilocarpine-treated mice. Mice were monitored behaviorally for seizure activity and the onset of status epilepticus (SE) was noted as previously described [23]. After 3 hours of SE, all mice—including saline controls—received two injections of diazepam 10 min apart (10 mg/kg, s.c.) to mitigate seizure activity. For the next 48h mice were given sterile Ringer’s (saline) solution 2–3 times daily for hydration support and access to soft diet. Mice were video-monitored throughout the entire experiment. Body weight was assessed once weekly in all mice until the end of the experiment. To confirm the presence of spontaneous seizures, 3 days of video data collected in the 6th week after SE were reviewed. Seizures were classified as either Class II/III or IV/V using a modified Racine scale [26]. In the present experiment 10% of pilocarpine-treated mice died during SE and another 14% died (or were euthanized due to declining health) over the following days. Overall mortality among pilocarpine-treated mice was 24% (5 of 21). No control mice died. Final cohorts were as follows: Cohort 1 (n = 7 SE mice, n = 9 Controls) Cohort 2 (n = 9 SE mice, n = 10 Controls). All 16 pilocarpine-treated mice had at least one Class V spontaneous seizure [Cohort 1: 9.7 ± 4.4 seizures/day, Cohort 2: 6.6 ± 2.1]. Cohort 1 was used for the assessment of HPA axis function and Cohort 2 was used for behavioral testing (Fig 1A).

### HPA axis assessment

Morning baseline corticosterone levels were obtained by collecting tail-nick blood 1 and 7 weeks after SE in cohort 1 mice and week 10 in mice of cohort 2. Eight weeks after SE, mice were exposed to restraint stress for 30min. For restraint stress, mice were placed in well ventilated conical tubes for 30min. Plasma samples were collected by tail nick at 0 (pre-stress), 15, 30, 60 and 120min after mouse placement in the restrainer. The 30min sample was collected while animals were inside the restrainer. All other plasma samples, including baseline measurements, were collected from freely-moving mice using a procedure that can be completed in under 3 min (the minimal response time for HPA axis activation in rodents [27]), to minimize stress [28]. Immediately after the 120min plasma collection, mice were given pentobarbital (100 mg/kg i.p) and transcardially perfused with saline followed by 2.5% paraformaldehyde + 4% sucrose in 0.1M PBS. Brains were collected and sectioned on a microtome at 35 μm for immunohistochemistry.

Mice that exhibited a seizure up to 6 hours prior to or during restraint stress were excluded, in accord with past work suggesting that 6 hours is sufficient time to eliminate the confounding effect of acute seizures on corticosterone secretion [25]. Assessment of acute seizures was conducted using a combination of real-time observations by the experimenter and retrospective video analyses. Only one mouse exhibited a class V seizure during restraint stress. In addition, two 7-week samples were removed from cohort 1 and one baseline sample was removed from cohort 2 due to presence of seizure activity.

#### Corticosterone radioimmunoassay

Tail blood samples (~50μl) were collected into EDTA-treated microvette collection tubes and immediately placed on ice. All blood sample collections occurred within 4 h of lights on. Blood samples were centrifuged (6000 g, 15min, 4°C) to isolate the plasma, which was subsequently stored at -20°C. Plasma corticosterone levels were measured using 125I RIA kit (MP Biomedicals Inc., Orangeburg, NY) as previously described [23].
Organ collection

In order to assess the impact of epilepsy on stress-sensitive organs, adrenal and thymus glands from mice in cohort 2 were dissected, blotted on filter paper, allowed to dry and immediately weighed.

Behavioral assessment

6 weeks after SE, mice in cohort 2 underwent the sucrose preference test. The following week, 24h home cage monitoring was conducted, followed 72h later by open field testing. On week 8 mice were tested in the elevated plus maze, followed by testing in the forced swim test 9 weeks after SE. The open field, elevated plus maze and forced swim tests were performed between 09:00–12:00 under regular room lights.
Sucrose preference test. Sucrose preference, a measure of anhedonia, was assessed using singly-housed mice as previously described [29]. Mice were allowed to acclimate for 3 days to two water bottles. On the fourth day, the water in one of the bottles was replaced with sucrose solution (0.5%) for 24h, followed by an additional 24h period with water-only in each bottle. Beginning on the sixth day, a 48h sucrose preference test was performed by allowing mice to choose between bottles with either 1% sucrose or water. The bottles were reversed on the second day to control for side preference. Intake from each bottle and body weight were measured daily. Sucrose preference was calculated as the ratio of sucrose solution consumed divided by total fluid consumption over the 48hr period.

Home-cage activity monitoring. Twenty-four hour home cage activity was measured using the SmartFrame stainless steel cage rack frame (Lafayette Instrument Company, Lafayette, IN, USA) with infrared photo beam interruption sensors (7X and 15Y). Data were analyzed using HMM100 motor monitor software (Campden Instruments LTD, England) [30].

Open field. Mice were exposed to an open field apparatus consisting of a white 50 X 50 X 22 cm Plexiglas box. Each mouse was placed in the same initial corner facing the walls and allowed to freely explore for 5 min. The single testing session was video recorded. Videos were scored for total time spent in the periphery and center areas as well as distance travelled using Topscan software (Clever Sys Inc, Reston VA, RRID:SCR_014494). Behavioral freezing was analyzed using EthoVision XT software (Noldus, VA, RRID:SCR_000441).

Elevated plus maze. Exposure to the elevated plus maze was used as a measure of innate anxiety. The PVC apparatus consists of a 5 cm² center area from which two open (66 x 5 cm) and two enclosed (66 x 5 x 15 cm) arms radiate. Arms were 38 cm above the floor. For testing, each mouse was placed on the center square of the maze facing the same open arm. Video files were scored using Topscan software (Clever Sys Inc, Reston VA, RRID:SCR_014494) for time spent in the open vs. closed arms and total distance travelled. Freezing behavior was determined using EthoVision XT software (Noldus, VA, RRID:SCR_000441).

Forced swim test. Mice were exposed to a single 6 minute session as previously described [26]. The behavioral apparatus was a 2 L glass beaker filled with 1500 ml of water (30–33°C). Mice were placed in the cylinder for 6 min and the session was videotaped. Scoring was done by an observer blind to the experimental conditions. Behavior was scored by quantifying the time spent in (i) active struggling behaviors, defined as any movement of the limbs in and out of the water with the body parallel to the surface or as circular movement around the apparatus, and (ii) immobility, defined as periods when the mouse did not make any active movements or floated in the water without struggling.

Immunohistochemistry

Free-floating brain sections (35 μm) were placed in blocking solution (4% normal goat serum, 0.1% bovine serum albumin and 0.2% Triton-X in 0.1 M PBS) for 1h and subsequently incubated in rabbit anti-Fos (1:500 Santa Cruz Biotechnology Cat# sc-52, RRID: AB_2106783) and mouse anti-NeuN (1:500 Millipore Cat# MAB377, RRID:AB_2298772) antibodies for 24h at 4°C. Both primary antibodies are well-characterized [31,32] and have been used previously by our group [26,33,34]. Donkey anti-rabbit AlexaFluor 594 (1:500 Jackson ImmunoResearch Labs Cat# 711-585-152 RRID:AB_2340621) and goat anti-mouse AlexaFluor 488 (1:500 Jackson ImmunoResearch Labs Cat# 115-545-146 RRID:AB_2307324) antibodies were used to visualize the respective primary antibodies. Stained tissue sections were mounted onto gelatin-coated slides and coverslipped with Fluoromount-G mounting media. Three to four sections per animal were examined for each of the regions summarized in Fig 1B. Because acute seizures have been shown to increase Fos expression in the hippocampus [35], the one mouse
that was excluded from the restraint testing due to a seizure was also excluded from immuno-
histochemical assessment.

**Confocal imaging and cell quantification**

Images were obtained using a 3024 Nikon A1Rsi microscope (software RRID: SCR_014329) with a 40× water objective (NA 1.15, image size 317 × 317 μm in the XY plane). All images were collected with identical parameters and analyzed by an investigator blind to the experimental conditions to avoid bias. Three to four sections per brain region were analyzed. The regions analyzed (Fig 1B) were selected based on their known role in regulating the HPA axis response to stress [12,36,37]. We analyzed Fos activation in two areas of the medial prefrontal cortex (infralimbic and prelimbic), three subdivisions of the hippocampus (CA1, CA3 and dentate gyrus), three amygdala subdivisions (central, basal and lateral amygdala), the ventral subiculum and the paraventricular nucleus of the hypothalamus (Fig 1B). The proportion of Fos to NeuN positive cells in each region was determined from confocal z-series image stacks (0.33 μm step size through ~10 μm of tissue). All cell counts were conducted using Imaris Software (RRID: SCR_007370) and a variation of the optical dissector method [38,39]. Fluorescent "spots" automated detection method [40] was used to determine the number of immunopositive cells. A volume surface was created by tracing the region of interest (ROI) through the stack. Minimum fluorescent intensity and size criteria (>4.14 μm) were used for automated screening. The number of Fos and NeuN immunopositive cells were further reviewed by an investigator blinded to treatment group to remove false-positives and to identify false-negatives. Results are reported as percentages of total Fos positive cells over total NeuN positive cells to correct for any cell death.

**Statistics**

Statistical analyses were performed using GraphPad Prism software (version 7.0) or SigmaPlot Software (version 13.0). Unpaired t-test's with Welch's correction were performed to compare single measurements between epileptic and control mice. Statistical significance for all immunohistochemical analyses was determined using Sidak-Bonferroni corrections for multiple t-tests. 2 –Way Repeated Measures ANOVA with Holm-Sidak post-hoc analysis was employed to analyze corticosterone measurements following restraint stress, baseline secretion from cohort 1 and home cage monitoring of cohort 2 data. Statistical significance was set at p < 0.05. Data that failed tests of normality or equal variance were normalized using either square root or rank transformations. Values are presented as means of raw (non-transformed) data ± standard error of the mean (SEM).

**Results**

**Epileptic mice show elevated stress-induced and baseline corticosterone secretion**

Eight weeks after SE, mice from cohort 1 were exposed to restraint stress for 30 minutes. Blood samples to analyze corticosterone secretion were taken at 0, 30, 60 and 120 min from the onset of the stressor. Restraint produced a significant increase in corticosterone levels in both control and epileptic mice (Fig 2A; F[3,34] = 86.73, p<0.001, Two-way RM ANOVA with time-point and treatment as factors). Relative to pre-restraint levels (0 minutes) corticosterone was significantly increased at 30 minutes (p<0.001, Holm-Sidak method) and 60 minutes (p<0.001, Holm-Sidak) for both treatment groups. In addition, a significant interaction between timepoint and treatment was found (F[3,34] = 3.59, p<0.023). Post-tests revealed a
significantly greater corticosterone increase at the 30 minute timepoint in epileptic mice relative to controls (p<0.016, Holm-Sidak). Control and epileptic mice were statistically equivalent at 0 (p = 0.930), 60 (p = 0.205) and 120 (p = 0.235) minutes.

In addition to acute stress challenge, we also assessed baseline corticosterone levels. Morning baseline corticosterone secretion was elevated in epileptic mice compared to controls (Fig 2B; F[1,11] = 16.24, p = 0.002, Two-way ANOVA on ranked data with timepoint and treatment as factors). Post-tests revealed significantly greater corticosterone levels in epileptic mice vs. controls at both 1 week (p = 0.02, Holm-Sidak) and 7 weeks (p<0.001, Holm-Sidak). Epileptic mice from cohort 2 also showed increased morning baseline corticosterone secretion when measured at week 10 (Fig 2C; t = 2.352 df = 8.79, p = 0.022, t-test). Consistent with these findings, adrenal gland weight from epileptic cohort 2 mice was significantly increased relative to controls (Fig 2D; t = 2.469 df = 15.73, p = 0.0127, t-test). Thymus weight did not differ between groups (data not shown).

Reduced Fos expression in stress regulatory forebrain regions following restraint stress in epileptic mice

Restraint stress has consistently been found to increase Fos immunoreactivity in specific brain regions in control animals [26,33,41–47]. Consistent with these prior findings, control (non-SE) mice exposed to 30 minutes of restraint stress exhibited large numbers of Fos
immunoreactive neurons in both subdivisions of the medial prefrontal cortex (PFC), measured 120 min following stress induction. By contrast, Fos immunoreactive neurons were rare in epileptic mice following stress (Fig 3A & 3B; prelimbic $t = 3.356$ df = 12, $p = 0.01$; infralimbic $t = 2.731$ df = 12, $p = 0.03$; t-test with Sidak-Bonferroni corrections). Similarly, there were significantly fewer Fos immunoreactive neurons in the basal amygdala (Fig 3C & 3D; $t = 3.298$ df = 12, $p = 0.02$; t-test with Sidak-Bonferroni corrections) and the ventral subiculum (Fig 3E & 3F; $t = 4.56$ df = 12, $p = 0.003$; t-test) in epileptic mice. No significant differences were found in the hippocampus, or other amygdaloid subnuclei (Table 1). Epileptic mice exhibited a

---

Fig 3. Reduced expression of Fos in stress regulatory regions in epileptic mice. Representative micrographs showing Fos (red) and NeuN (green) immunoreactivity in A) the prelimbic region of the medial prefrontal cortex (PFC), C) the basal amygdala and E) ventral subiculum. Top panels in each set show control mice while bottom panels are from epileptic mice. Epileptic mice show decreased Fos expression in the B) prelimbic and infralimbic region of the PFC, D) the basal subdivision of the amygdaloid nucleus and F) the ventral subiculum relative to control mice. $^* p < 0.05$, $^{**} p < 0.01$. Data presented as mean ± SEM, n = 6–8 mice per group.

https://doi.org/10.1371/journal.pone.0197955.g003
significant reduction in NeuN+ cells in the CA3 region of the hippocampus (Table 1; t = 3.075 df = 12, p = 0.03), fitting the known pattern of SE-induced cell loss in this model. NeuN+ cell densities were statistically similar between epileptic and control mice for all other regions analyzed (Table 1).

Epileptic mice display anxiety-like behaviors

Epileptic mice exhibited a significant reduction in the percentage of time spent in the center of the open field relative to controls (Fig 4A; t = 3.189 df = 7.458, p = 0.014, t-test). Epileptic mice also displayed a reduction in the total distance travelled in the open field (Fig 4B; t = 4.842 df = 14.34, p = 0.0002, t-test) and exhibited significantly more freezing behavior, defined as the complete absence of movement—except for breathing—lasting >2s (Fig 4C; t = 4.846 df = 15.09, p = 0.0002, t-test). Similarly, in the elevated plus maze, epileptic mice avoided the open arms (Fig 4D; t = 3.592 df = 13.81, p = 0.003, t-test) and showed a reduction on the total distance travelled (Fig 4E; t = 2.648 df = 16, p = 0.0176, t-test). Epileptic mice also exhibited increased freezing behavior in the plus maze (Fig 4F; t = 4.449 df = 15.38, p = 0.0004, t-test), similar to that observed in the open field. Reduced movement in the maze trials, however, does not appear to reflect an overall decrease in mobility or ill health, as 24 hour home-cage activity monitoring revealed that epileptic mice were more active than controls. (Fig 4G; F[23,368] = 5.329, p<0.001; two-way ANOVA on ranked data showing significant interactions between timepoint and treatment). Post-tests revealed a significant increase in activity between 21:00–06:00 (p<0.001, Holm-Sidak) of epileptic mice relative to controls. Importantly, behavioral testing was done during the light phase, when epileptic and control mice displayed similar activity levels (09:00–13:00).

Epileptic mice exhibit increased anhedonic behaviors, but not increased passive coping behaviors

The sucrose preference test was used as a measure of anhedonia, a behavior that is commonly observed in humans with major depressive disorder. Epileptic mice showed reduced

Table 1. Fos expression quantification.

| Region                          | NeuN+ Cells | Fos+ Cells | %Fos+/NeuN+ Cells |
|---------------------------------|-------------|------------|-------------------|
|                                | Control     | Post-SE    | Control           | Post-SE    | Control | Post-SE |
| PFC PL                          | 786±45      | 766±58     | 104±24            | 17±10*     | 12.96±2.86 | 2.05±1.19* |
| IL                              | 512±25      | 479±53     | 57±16             | 13±7*      | 10.76±2.68 | 2.38±1.16* |
| AMY Basal                       | 356±33      | 466±16     | 40±5              | 28±6*      | 11.53±1.20 | 6.03±3.11* |
| Lateral                         | 255±18      | 285±10     | 19±7              | 11±3       | 7.09±2.05 | 3.75±0.91  |
| Central                         | 304±20      | 367±50     | 10±2              | 14±4       | 3.34±0.60 | 4.21±1.42  |
| HIPP CA1                        | 188±5       | 183±14     | 2±1               | 2±2        | 1.12±0.31 | 1.14±0.86  |
| CA3                             | 249±11      | 148±39*    | 10±1              | 5±2        | 4.14±0.51 | 3.78±1.16  |
| DG                              | 1502±56     | 1426±75    | 23±6              | 8±2        | 1.47±0.35 | 0.56±0.15  |
| Ventral Subiculum               | 504±10      | 513±27     | 24±3              | 5±3*       | 4.71±0.67 | 0.94±0.48* |
| PVN                             | 300±14      | 283±26     | 134±14            | 108±4      | 44.39±3.53 | 39.19±3.16 |

Group averages showing the number of NeuN+ and Fos+ cells per region are shown in columns 2 and 3: The rows represent infralimbic (IL) and prelimbic (PL) medial prefrontal cortex (PFC); basal, lateral and central amygdala (AMY); CA1, CA3 and dentate gyrus (DG) of hippocampus (HIPP); ventral subiculum and paraventricular nucleus of the hypothalamus (PVN). To control for cell loss, the number of Fos+ cells was normalized to the number of NeuN+ cells and converted to a percentile (Fos+/NeuN+ X 100). Data are reported as means ± SEM. n = 6–8 mice per group.

https://doi.org/10.1371/journal.pone.0197955.t001

**Epileptic mice display anxiety-like behaviors**

**Epileptic mice exhibit increased anhedonic behaviors, but not increased passive coping behaviors**

The sucrose preference test was used as a measure of anhedonia, a behavior that is commonly observed in humans with major depressive disorder. Epileptic mice showed reduced
preference for the 1% sucrose solution when compared to control mice (Fig 5A, t = 2.201, df = 10.65, p = 0.03, t-test). The forced swim test was used to assess coping behavior. Epileptic mice displayed more frequent active behaviors than control mice (Fig 5B, t = 2.976, df = 16, p = 0.017, t-test). No significant differences were observed in the percent of time spent immobile in the forced swim test.

Discussion
Our results demonstrate that the induction of epilepsy in mice causes profound decreases in activation of key brain circuits that are responsible for the control of stress reactivity and
emotional behavior. Loss of forebrain stress reactivity is associated with enhanced glucocorticoid secretion in response to acute stress. Importantly, pilocarpine-induced epilepsy also increases anxiety- and depression-like behaviors thought to be regulated by prefrontal and hippocampal circuits. Such findings are consistent with the increased incidence of anxiety and depressive disorders observed in patients with epilepsy, and suggest that epilepsy produces an organic brain dysfunction in key stress-regulatory circuits that may increase vulnerability for the development of psychological disorders.

Endocrine dysregulation occurs during epileptogenesis and persists through the chronic epileptic period

Pilocarpine SE induces a rapid increase in glucocorticoid secretion, evident as early as 2 hours after SE in mice [24]. Here, we show that glucocorticoid hypersecretion is present 1 week after SE, before spontaneous seizures were observed, and 7 and 10 weeks after SE, when spontaneous seizures were frequent. The findings are consistent with previous reports [23,25]. Although the data suggest that glucocorticoid hypersecretion at 1 week may be a consequence of SE, we cannot exclude the possibility that increased secretion was driven by undetected spontaneous seizures. Additionally, we report an increase in adrenal gland weight at 10 weeks post-SE, indicative of increased adrenal drive.

Epileptic mice were hyper-responsive to acute restraint stress, showing elevated peak corticosterone secretion. This hyper-responsiveness is reminiscent of that observed in a subset of patients with TLE [13,14]. Damage to the hippocampus, either due to the initial period of status or recurrent seizures, may be responsible for the glucocorticoid hypersecretion seen in epileptic mice. A number of lesion studies implicate the hippocampus in inhibition of basal (circadian nadir) corticosterone secretion [37]. Hippocampal damage is characteristic in humans with temporal lobe epilepsy, and in animal models of the disease [3,48–50]. Loss of CA3 pyramidal cells was observed in the present study, predictive of disrupted hippocampal output. Indeed, glucocorticoids play an important role in regulating hippocampal neuronal viability following excitotoxic insults such as exposure to kainic acid [51]. Consequently, it is plausible that the observed increases in baseline morning corticosterone may be linked to pathological changes in the hippocampus of post-SE mice. However, SE has the capacity to
affect the entire brain, and we cannot exclude the possibility that damage to other regions contributes to endocrine dysfunction.

**Stress modulatory forebrain circuits are disrupted in chronic epilepsy**

Fos is the protein product of immediate early gene c-Fos which is expressed and detectable within minutes to hours following an acute cellular stimulus [52–54]. Under unstressed conditions, Fos expression is minimal [42,44,55]. However, exposure to acute stress produces robust increases in Fos protein in numerous brain regions, including the prefrontal cortex and the paraventricular nucleus of the hypothalamus in mouse and rat [26,33,41–47].

Strikingly, 30 minutes after restraint challenge, Fos protein levels in epileptic mice were significantly lower than controls in the medial prefrontal cortex, basal amygdala and ventral subiculum. We cannot directly compare induction seen in epileptic mice to those of unstressed controls, so it is not possible to conclude that these regions are inactive. However, it is clear that Fos reactivity is substantially less than that observed in stressed non-SE mice, consistent with disengagement of corticolimbic stress circuitry. Importantly, we are not aware of other SE-related mitigating factors that cause pronounced reductions in stress-induced Fos. Elevated Fos levels are evident 15 minutes after spontaneous seizures in the rodent pilocarpine model [35], but Barros and colleagues [56], report that Fos levels return to baseline by 6 hours after a pentylentetrazole-evoked seizure. Exclusion of animals exhibiting behavioral seizures up to 6 hours before testing in the present study should minimize the effect of post-ictal changes in Fos levels, although it remains possible that the post-ictal influence on Fos extends beyond this time frame. Nevertheless, the fact that Fos is minimally induced in the prefrontal cortex, amygdala and ventral subiculum of epileptic mice is remarkable and unique, and suggests compromised integrity of stress-regulatory circuitry.

The recruitment of forebrain structures is thought to modulate activation of the HPA axis, providing top-down regulation of the stress response [57]. Reduced activation of the prefrontal cortex and/or ventral subiculum is likely to reduce corticolimbic inhibition of the HPA axis [58,59], perhaps explaining the observed enhancement of stress reactivity in epileptic mice. The role of the basal amygdala in stress regulation is complex. The structure is known to be activated by restraint stress, however, stimulation can lead to either reduced or increased corticosterone secretion [37]. Thus, reduced activation of the basal amygdala nucleus may also contribute to HPA axis hyperactivity.

We did not find a significant difference between epileptic and control mice in the number of Fos expressing cells in the paraventricular nucleus of the hypothalamus (PVN), which is the central driver of the HPA axis. However, it is important to note that Fos protein is an indirect all-or-none reporter of neuronal activation, and is not necessarily expressed at levels proportional to the extent of activity. It is possible that a robust initial activation of the PVN occurs following stress exposure in both control and epileptic mice, occluding any subsequent differences in Fos protein levels between the groups. Moreover, single time point analyses do not assess the strength or persistence of PVN drive, which may differ between SE and non-SE groups. Although widely used as a physiological marker of neuronal activity following acute stress, it is possible that Fos is not as sensitive as other biomarkers in the PVN of our model. Recent data suggest that biomarkers such as FosB/ΔFosB and p-ERK1/2 are useful markers to define the aggravation of seizures in mice, and both present activation patterns that are brain region specific [60,61]. It is also possible that HPA drive induced by SE may enhance the releasable pool of ACTH secretagogues in the median eminence (e.g., CRH and arginine vasopressin), which could increase the amount of pituitary drive per given PVN stimulatory...
episode. Finally, there are numerous other mechanisms that may drive PVN neurons via parallel alternative signaling pathways.

**Aberrant forebrain circuits in TLE may contribute to endocrine and emotional dysregulation**

Abnormalities in the stress response have been noted in patients with TLE [14]. In some patients, evoking an emotional stressful response (i.e. using audio and video recordings) is sufficient to trigger spontaneous seizures [62]. In line with our Fos data, patients with epilepsy demonstrate impairments in the activation and functional connectivity of limbic networks at rest [63–66] and in response to stress [14]. Therefore, hypo-activity of these regions may result in reduced inhibitory control over the HPA axis. Studies in humans also suggest that PFC hypofunction may contribute to the development of major depressive illness [67]. In rodents, BALB/c mice, a strain considered to be stress-sensitive and often used as a model of ‘anxiety-like’ behavior, have reduced Fos activation in the medial prefrontal cortex following restraint stress relative to C57BL/6 mice [55]. This suggests a link between reduced prefrontal Fos and enhanced stress reactivity. Additionally, hypoactivation of the PFC and ventral subiculum may increase amygdala excitability [68], and thereby contribute to the development of anxiety-like behaviors. Therefore, the aberrant recruitment of these circuits may have repercussions at the neuroendocrine and behavioral level in TLE [69].

**Epileptic FVB male mice show increased anxiety-like behaviors, hyperactivity and anhedonia**

Emotional abnormalities have been found consistently in the pilocarpine SE model in rats [70] and female mice of several strains [29,71,72]. These findings indicate that enhanced emotionality is a reliable and reproducible consequence of TLE in mice, and suggest that similar mechanisms may underlie emotional dysregulation seen in TLE patients. In this study we performed a battery of behavioral tests on male FVB mice, a strain that shows better survival in the pilocarpine model than the C57BL/6 strain typically used in behavioral studies [22,40]. Similar to epileptic female NMRI mice [72], epileptic male FVB mice showed freezing-like behaviors when exposed to novelty, a behavior that is in contrast with the thigmotaxis observed in the C57BL/6 strain [71]. Although we did not see any convulsive seizures or seizure-like activity (CII/CIII Racine scale) during testing, the possibility that freezing reflects non-convulsive seizures cannot be excluded. However, the consistency of the behavioral data from our study and that performed in NMRI females [72] leads us to favor the interpretation that freezing behavior in response to a novel environment reflects a passive coping behavior consistent with an anxiety-like response [73]. Moreover, epileptic FVB males exhibited hyperactivity during home-age monitoring, suggesting that lack of movement in the open field and elevated plus maze are not related to general hypolocomotion. Hyperactive behaviors have been observed in epileptic female mice [71,72] and rats [74], further suggesting that decreased activity is not linked to locomotor deficits. Thus, the observation of freezing in the open field and elevated plus maze, despite overall hyperactivity, may suggest a potential disruption in the fear-anxiety response.

To assess depression-like behaviors, we employed the forced swim test and the sucrose preference test. These two tests measure two different putative phenotypes, passive coping and anhedonia, respectively, that parallel commonly observed symptoms in patients with major depression. In our experiment, and similar to previous observations [71,72], mice did not exhibit increased passive coping (the adoption of an immobile posture) in the forced swim test relative to controls. In contrast the sucrose preference test revealed an anhedonic response; consistent with a depressive-like phenotype. These observations are consistent with prior...
studies in epileptic mice [29,75]. Absence of an increased immobility phenotype in the forced swim test, despite the presence of anhedonia, may indicate that circuits disrupted in this epilepsy model do not control coping behavior in this context. Alternatively, impairments in memory and potential hyperactivity, previously reported in epileptic mice, may interfere with the sensitivity of this test [71,72].

The forced swim test was developed as a tool to screen for antidepressant efficacy and to investigate different coping strategies [76]; and not necessarily to directly measure depressive-like behavior. In our study, epileptic mice displayed struggling activity at a greater frequency than non-epileptic control mice while displaying no differences in time spent immobile. Recent optogenetic experiments demonstrate that activation of a subset of neurons located in the medial prefrontal cortex is necessary to drive the transition between active swimming and immobility behaviors in the forced swim test [77]. Thus, it is possible that impaired recruitment of the prefrontal cortex in the context of swim stress leads to impairment in the transition between active and passive behaviors.

The present study does not allow us to discern whether the endocrine, cellular and behavioral abnormalities evident in epileptic mice are due to the initial precipitating injury (SE), the epilepsy itself (recurrent seizures), chronic exposure to excess glucocorticoids or some combination thereof. However, prior work implicates glucocorticoids in the progression of the negative consequences of SE. For example, work in our group demonstrates that treatment with the glucocorticoid receptor antagonist, mifepristone, reduces both HPA axis hyperactivity and SE-related hippocampal pathology [23]. Moreover, infusion of glucocorticoids enhances epileptiform activity in SE mice [78]. Studies in humans and rats have shown that traumatic brain injury (a type of precipitating injury) is associated with the development of HPA axis hyperactivity prior to the development of seizures [79,80] suggesting that the precipitating injury could result in endocrine dysfunction. Similarly, evidence suggests that epilepsy itself, as seen in genetic models, may lead to endocrine dysfunction and behavioral comorbidities [81,82]. Most patients with epilepsy who exhibit psychiatric comorbidities do not have a history of SE, and behavioral dysfunction is evident in epilepsy models without SE. SE, therefore, is not a required element. Questions of causality still remain, however, as the underlying brain dysfunction that caused the epilepsy could directly cause HPA dysfunction, or secondarily produce it via inducing epilepsy. Elucidating the causal relationships among these variables will remain a topic of intense study.

Acknowledgments
We thank the CCHMC Confocal Core for their advice on image acquisition.

Author Contributions
Conceptualization: Aynara C. Wulsin, Ana Franco-Villanueva, Rachel L. Morano, Brittany L. Smith, Benjamin A. Packard, Steve C. Danzer, James P. Herman.
Data curation: Aynara C. Wulsin, Christian Romancheck, Steve C. Danzer, James P. Herman.
Formal analysis: Aynara C. Wulsin, Christian Romancheck.
Funding acquisition: Aynara C. Wulsin, James P. Herman.
Investigation: Aynara C. Wulsin, Steve C. Danzer, James P. Herman.
Methodology: Aynara C. Wulsin, Ana Franco-Villanueva, Rachel L. Morano, Brittany L. Smith, Benjamin A. Packard, Steve C. Danzer, James P. Herman.
Project administration: Aynara C. Wulsin, Benjamin A. Packard, Steve C. Danzer, James P. Herman.

Resources: Aynara C. Wulsin, Steve C. Danzer, James P. Herman.

Supervision: Steve C. Danzer, James P. Herman.

Validation: Aynara C. Wulsin.

Visualization: Aynara C. Wulsin.

Writing – original draft: Aynara C. Wulsin.

Writing – review & editing: Aynara C. Wulsin, Steve C. Danzer, James P. Herman.

References

1. Curia G, Lucchi C, Vinet J, Guattieri F, Marinelli C, Torsello A, et al. Pathophysiogenesis of mesial temporal lobe epilepsy: is prevention of damage antiepileptogenic? Curr Med Chem. 2014; 21: 663–88. https://doi.org/10.2174/0929867320666131119122201 PMID: 24251666

2. Engel J. Introduction to temporal lobe epilepsy. Epilepsy Res. 1996; 26: 141–50. PMID: 8985696

3. Curia G, Longo D, Biagini G, Jones RSG, Avoli M. The pilocarpine model of temporal lobe epilepsy. J Neurosci Methods. 2008; 172: 143–57. https://doi.org/10.1016/j.jneumeth.2008.04.019 PMID: 18550176

4. Wieser H-G. ILAE Commission Report. Mesial temporal lobe epilepsy with hippocampal sclerosis. Epilepsia. 2004; 45: 695–714. https://doi.org/10.1111/j.0013-9580.2004.09004.x PMID: 15144438

5. Sousa R, Boulland J-L, Bassot E, Bras H, Coulon P, Chaudhry FA, et al. Reorganization of supramamillary–hippocampal pathways in the rat pilocarpine model of temporal lobe epilepsy: evidence for axon terminal sprouting. Brain Struct Funct. 2015; 220: 2449–2468. https://doi.org/10.1007/s00429-014-0800-2 PMID: 24889162

6. Suleymanova EM, Gulyaev MV, Abbasova KR. Structural alterations in the rat brain and behavioral impairment after status epilepticus: an MRI study. Neuroscience. 2016; 315: 79–90. https://doi.org/10.1016/j.neuroscience.2015.11.061 PMID: 26674057

7. Hester MS, Danzer SC. Hippocampal granule cell pathology in epilepsy—a possible structural basis for comorbidities of epilepsy? Epilepsy Behav. Elsevier Inc.; 2014; 2–13. https://doi.org/10.1016/j.yebeh.2013.12.022 PMID: 24468242

8. Kanner AM. Depression in epilepsy: prevalence, clinical semiology, pathogenic mechanisms, and treatment. Biol Psychiatry. 2003; 54: 388–398. https://doi.org/10.1016/S0006-3223(03)00469-4 PMID: 12893113

9. Kondziella D, Alvestad S, Vaaler A, Sonnewald U. Which clinical and experimental data link temporal lobe epilepsy with depression? J Neurochem. 2007; 103: 2136–52. https://doi.org/10.1111/j.1471-4159.2007.04926.x PMID: 17887964

10. Herman JP, Ostrander MM, Mueller NK, Figueiredo H. Limbic system mechanisms of stress regulation: hypothalamo-pituitary-adrenocortical axis. Prog Neuropsychopharmacol Biol Psychiatry. 2005; 29: 1201–13. https://doi.org/10.1016/j.pnpbp.2005.08.006 PMID: 16271821

11. Jankord R, Herman JP. Limbic regulation of hypothalamic-pituitary-adrenocortical function during acute and chronic stress. Ann N Y Acad Sci. 2008; 1148: 64–73. https://doi.org/10.1196/annals.1410.012 PMID: 19120092

12. Herman JP, McQveen JM, Ghosal S, Kopp B, Wulsin A, Makinson R, et al. Regulation of the Hypothalamic-Pituitary-Adrenocortical Stress Response. Comprehensive Physiology. Hoboken, NJ, USA: John Wiley & Sons, Inc.; 2016. pp. 603–621. https://doi.org/10.1002/cphy.c150015 PMID: 27085163

13. Zobel A, Wellmer J, Schulze-Rauschenbach S, Pfeiffer U, Schnell S, Elger C, et al. Impairment of inhibitory control of the hypothalamic pituitary adrenocortical system in epilepsy. Eur Arch Psychiatry Clin Neurosci. 2004; 254: 303–11. https://doi.org/10.1007/s00406-004-0499-9 PMID: 15365705

14. Allendorfer JB, Heyse H, Mendoza L, Nelson EB, Eliassen JC, Storrs JM, et al. Physiologic and cortical response to acute psychosocial stress in left temporal lobe epilepsy—a pilot cross-sectional fMRI study. Epilepsy Behav. 2014; 36: 115–23. https://doi.org/10.1016/j.yebeh.2014.05.003 PMID: 24907497

15. McEwen BS, Nasca C, Gray JD. Stress Effects on Neuronal Structure: Hippocampus, Amygdala and Prefrontal Cortex. Neuropsychopharmacology. Nature Publishing Group; 2015; 1–21. https://doi.org/10.1038/npp.2015.171 PMID: 26076834
16. Sapolsky RM. Glucocorticoids and Hippocampal Atrophy in Neuropsychiatric Disorders. Arch Gen Psychiatry. American Medical Association; 2000; 57: 925. https://doi.org/10.1001/archpsyc.57.10.925

17. Kling MA, Coleman VH, Schulkin J. Glucocorticoid inhibition in the treatment of depression: can we think outside the endocrine hypothalamus? Depress Anxiety. 2009; 26: 641–9. https://doi.org/10.1002/da.20546 PMID: 19133699

18. Marques AH, Silverman MN, Sternberg EM. Glucocorticoid dysregulations and their clinical correlates: From receptors to therapeutics. Ann N Y Acad Sci. 2009; 1179: 1–18. https://doi.org/10.1111/j.1749-6632.2009.04987.x PMID: 19906229

19. Pariante CM, Lightman SL. The HPA axis in major depression: classical theories and new developments. Trends Neurosci. Elsevier; 2008; 31: 464–8. https://doi.org/10.1016/j.tins.2008.06.006 PMID: 18675469

20. Cavaleiro EA, Leite JP, Bortolotto ZA, Turski WA, Ikonomidou C, Turski L. Long-term effects of pilocarpine in rats: structural damage of the brain triggers kindling and spontaneous recurrent seizures. Epilepsia. 1991; 32: 778–82. PMID: 1743148

21. Shibley H, Smith BN. Pilocarpine-induced status epilepticus results in mossy fiber sprouting and spontaneous seizures in C57BL/6 and CD-1 mice. Epilepsy Res. 2002; 49: 109–20. PMID: 12049799

22. Buckmaster PS, Haney MM. Factors affecting outcomes of pilocarpine treatment in a mouse model of temporal lobe epilepsy. Epilepsy Res. 2012; 102: 153–159. https://doi.org/10.1016/j.eplepsyres.2012.05.012 PMID: 22721955

23. Wulsin AC, Herman JP, Danzer SC. RU486 Mitigates Hippocampal Pathology Following Status Epilepticus. Front Neurol. 2016; 7: 1–7.

24. O’Toole KK, Hooper A, Wakefield S, Maguire J. Seizure-induced disinhibition of the HPA axis increases seizure susceptibility. Epilepsy Res. 2014; 108: 29–43. https://doi.org/10.1016/j.eplepsyr es.2013.10.013 PMID: 24225328

25. Mazarati AM, Shin D, Kwon YS, Bragin A, Pineda E, Tio D, et al. Elevated plasma corticosterone level and depressive behavior in experimental temporal lobe epilepsy. Neurobiol Dis. Elsevier Inc.; 2009; 34: 457–61. https://doi.org/10.1016/j.nbd.2009.02.018 PMID: 19285131

26. Wulsin AC, Herman JP, Solomon MB. Milfepristone decreases depression-like behavior and modulates neuroendocrine and central hypothalamic-pituitary-adrenocortical axis responsiveness to stress. Psychoneuroendocrinology. 2010; 35: 1100–12. https://doi.org/10.1016/j.psyneuen.2010.01.011 PMID: 2149549

27. Vahl TP, Ulrich-Lai YM, Ostrander MM, Dolgas CM, Elfers EE, Seeley RJ, et al. Comparative analysis of ACTH and corticosterone sampling methods in rats. Am J Physiol Endocrinol Metab. 2005; 289: E823–8. https://doi.org/10.1152/ajpendo.00122.2005 PMID: 15956051

28. Mahbod P, Smith EP, Fitzgerald ME, Morano RL, Packard BA, Ghosal S, et al. Desacyl Ghrelin Decreases Anxiety-like Behavior in Male Mice. Endocrinology. 2018; 159: 388–399. https://doi.org/10.1210/en.2017-00540 PMID: 29155981

29. Klein S, Bankstahl JP, Löscher W, Bankstahl M. Sucrose consumption test reveals pharmacoresistant depression-associated behavior in two mouse models of temporal lobe epilepsy. Exp Neurol. 2014; 263:263–71. https://doi.org/10.1016/j.expneu rol.2014.09.004 PMID: 25220610

30. Vollmer LL, Ghosal S, McGuire JL, Ahlbrand RL, Li K-Y, Santin JM, et al. Microglial Acid Sensing Regulates Carbon Dioxide-Evoked Fear. Biol Psychiatry. 2016; 80: 541–551. https://doi.org/10.1016/j.biopsych .2016.04.022 PMID: 27422366

31. Varga D, Herédii J, Kánvási Z, Ruszka M, Kis Z, Ono E, et al. Systemic L-Kynurenine sulfate administration disrupts object recognition memory, alters open field behavior and decreases c-Fos immunopositivity in C57Bl/6 mice. Front Behav Neurosci. 2015; 9: 157. https://doi.org/10.3389/fnbeh.2015.00157 PMID: 26136670

32. Yang J-X, Hua L, Li Y-Q, Jiang Y-Y, Han D, Liu H, et al. Caveolin-1 in the Anterior Cingulate Cortex Modulates Chronic Neuropathic Pain via Regulation of NMDA Receptor 2B Subunit. J Neurosci. 2015; 35: 36–52. https://doi.org/10.1523/JNEUROSCI.1161-14.2015 PMID: 25568101

33. Figueiredo HF, Bruestle A, Bodie B, Dolgas CM, Herman JP. The medial prefrontal cortex differentially regulates stress-induced c-fos expression in the forebrain depending on type of stressor. Eur J Neurosci. 2003; 18: 2357–64. PMID: 14622198

34. Solomon MB, Jones K, Packard BA, Herman JP. The Medial Amygdala Modulates Body Weight but not Neuroendocrine Responses to Chronic Stress. J Neuroendocrinol. 2010; 22: 13–23. https://doi.org/10.1111/j.1365-2826.2009.01933.x PMID: 19912476

35. Peng Z, Houser CR. Temporal patterns of fos expression in the dentate gyrus after spontaneous seizures in a mouse model of temporal lobe epilepsy. J Neurosci. 2005; 25: 7210–7220. https://doi.org/10.1523/JNEUROSCI.0838-05.2005 PMID: 16079403
36. Myers B, McKlveen JM, Herman JP. Neural Regulation of the Stress Response: The Many Faces of Feedback. Cell Mol Neurobiol. 2012; https://doi.org/10.1007/s10571-012-9801-y PMID: 22302180

37. Herman JP, Figueiredo H, Mueller NK, Ulrich-Lai Y, Ostrander MM, Choi DC, et al. Central mechanisms of stress integration: Hierarchical circuitry controlling hypothalamo-pituitary-adrenocortical responsiveness. Front Neuroendocrinol. 2003; 24: 151–180. https://doi.org/10.1016/j.yfne.2003.07.001 PMID: 14596810

38. Howell K, Hopkins N, Moloughlin P. Combined confocal microscopy and stereology: a highly efficient and unbiased approach to quantitative structural measurement in tissues. Exp Physiol. 2002; 87: 747–56. PMID: 12530405

39. Hester MS, Hosford BE, Santos VR, Singh SP, Rolle IJ, LaSarge CL, et al. Impact of rapamycin on status epilepticus induced hippocampal pathology and weight gain. Exp Neurol. 2016; 280: 1–12. https://doi.org/10.1016/j.expneurol.2016.03.015 PMID: 26995324

40. Hosford B, Liska J, Danzer S. Ablation of Newly-generated Hippocampal Granule Cells has Disease-Modifying Effects in Epilepsy. J Neurosci. 2016; in press.

41. Weinberg MS, Girotti M, Spencer RL. Restraint-induced fra-2 and c-fos expression in the rat forebrain: two types of acute restraint stress. Brain Res Bull. 2000; 52: 171–82. PMID: 10822158

42. Singewald N. Altered brain activity processing in high-anxiety rodents revealed by challenge paradigms and functional mapping. Neurosci Biobehav Rev. 2007; 31: 18–40. https://doi.org/10.1016/j.neubiorev.2006.02.003 PMID: 16620984

43. Chowdhury GM, Fujikata T, Nakamura S. Induction and adaptation of Fos expression in the rat brain by two types of acute restraint stress. Brain Res Bull. 2000; 52: 171–82. PMID: 10822158

44. Mustafa T, Jiang SZ, Eiden AM, Weihe E, Thistlethwaite I, Eiden LE. Impact of PACAP and PAC1 receptor deficiency on the neurochemical and behavioral effects of acute and chronic restraint stress in male C57BL/6 mice. Stress. NIH Public Access; 2015; 18: 408–18. https://doi.org/10.3109/10253890.2015.1025044 PMID: 25853791

45. Matsuda S, Peng H, Yoshimura H, Wen T-C, Fukuda T, Sakanaka M. Persistent c-fos expression in the brains of mice with chronic social stress. Neurosci Res. 1996; 26: 157–170. https://doi.org/10.1016/S0168-0102(96)01088-7 PMID: 8953578

46. Tsukiyama N, Saida Y, Kakuda M, Shintani N, Hayata A, Morita Y, et al. PACAP centrally mediates emotional stress-induced corticosterone responses in mice. Stress. Taylor & Francis; 2011; 14: 368–75. https://doi.org/10.3109/10253890.2010.544345 PMID: 21438773

47. Bernasconi N, Bernasconi A, Caramanos Z, Antel SB, Andermann F, Arnold DL. Mesial temporal damage in temporal lobe epilepsy: a volumetric MRI study of the hippocampus, amygdala and parahippocampal region. Brain. 2003; 126: 462–9. PMID: 12538412

48. Mathern GW, Adelson PD, Cahen LD, Leite JP. Hippocampal neuron damage in human epilepsy: Meyer’s hypothesis revisited. Prog Brain Res. 2002; 135: 237–51. PMID: 12143344

49. do Nascimento AL, Dos Santos NF, Campos Pelágo F, Aparecida Teixeira S, de Moraes Ferrari EA, Langone F. Neuronal degeneration and gliosis time-course in the mouse hippocampal formation after pilocarpine-induced status epilepticus. Brain Res. 2012; 1470: 98–110. https://doi.org/10.1016/j.expneurol.2016.03.015 PMID: 26995324

50. McCullers DL, Herman JP. Adrenocorticosteroid receptor blockade and excitotoxic challenge regulate adrenocorticosteroid receptor mRNA levels in hippocampus. J Neurosci Res. 2001; 64: 277–83. https://doi.org/10.1002/jnr.1076 PMID: 11319772

51. McClure JS, Krug SJ, Rodriguez-Justo M, Herman JP. Opiate receptor blockade delays the onset of pilocarpine-induced status epilepticus in the mouse hippocampus. Brain Res. 2006; 1108: 71–7. PMID: 16620984

52. O’Mahony CM, Sweeney FF, Daly E, Dinan TG, Cryan JF. Restraint stress-induced brain activation patterns in two strains of mice differing in their anxiety behaviour. Behav Brain Res. 2010; 213: 148–154. https://doi.org/10.1016/j.bbr.2010.04.038 PMID: 20435071

53. Barros VN, Mundim M, Galindo LT, Bittencourt S, Porcionatto M, Mello LE. The pattern of c-Fos expression and its refractory period in the brain of rats and monkeys. Front Cell Neurosci. 2015; 9: 72. https://doi.org/10.3389/fncel.2015.00072 PMID: 25814929
57. Ulrich-Lai YM, Herman JP. Neural regulation of endocrine and autonomic stress responses. Nat Rev Neurosci. 2009; 10: 397–409. https://doi.org/10.1038/nrn2647 PMID: 19469025

58. Herman JP, Mueller NK. Role of the ventral subicum in stress integration. Behav Brain Res. 2006; 174: 215–24. https://doi.org/10.1016/j.bbr.2006.05.035 PMID: 16876265

59. McKeeen JM, Myers B, Herman JP. The Medial Prefrontal Cortex: Coordinator of Autonomic, Neuroendocrine, and Behavioral Responses to Stress. J Neuroendocrinol. 2015; 27: 446–456. https://doi.org/10.1111/jne.12272 PMID: 25730797

60. Giordano C, Vinet J, Curia G, Biagini G. Repeated 6-Hz Corneal Stimulation Progressively Increases FosB/ΔFosB Levels in the Lateral Amygdala and Induces Seizure Generalization to the Hippocampus. Gross RE, editor. PLoS One. 2015; 10: e0141221. https://doi.org/10.1371/journal.pone.0141221 PMID: 26555229

61. Giordano C, Costa AM, Lucchi C, Leo G, Brunel L, Fehrentz J-A, et al. Progressive Seizure Aggravation in the Repeated 6-Hz Corneal Stimulation Model Is Accompanied by Marked Increase in Hippocampal p-ERK1/2 Immunoreactivity in Neurons. Front Cell Neurosci. 2016; 10: 281. https://doi.org/10.3389/fncel.2016.00281 PMID: 28018175

62. Feldman RG, Paul NL. Identity of emotional triggers in epilepsy. J Nerv Ment Dis. 1976; 162: 345–53. PMID: 1262858

63. Spencer SS. Neural Networks in Human Epilepsy: Evidence of and Implications for Treatment. Epilepsia. 2002; 43: 219–227. https://doi.org/10.1046/j.1528-1157.2002.26901.x PMID: 11906505

64. Haneef Z, Lenartowicz A, Yeh HJ, Levin HS, Engel J, Stern JM. Functional connectivity of hippocampal networks in temporal lobe epilepsy. Epilepsia. 2014; 55: 137–45. https://doi.org/10.1111/epi.12476 PMID: 24313957

65. Maccotta L, He BJ, Snyder AZ, Eisenman LN, Benzinger TL, Ances BM, et al. Impaired and facilitated functional networks in temporal lobe epilepsy. Neuroimage Clin. 2013; 2: 862–72. https://doi.org/10.1016/j.nic.2013.06.011 PMID: 24073391

66. Pittau F, Grova C, Moeller F, Dubau F, Gotman J. Patterns of altered functional connectivity in mesial temporal lobe epilepsy. Epilepsia. 2012; 53: 1013–23. https://doi.org/10.1111/j.1528-1167.2012.03464.x PMID: 22578020

67. Savitz JB, Drevets WC. Imaging phenotypes of major depressive disorder: genetic correlates. Neuroscience. 2009; 164: 300–30. https://doi.org/10.1016/j.neuroscience.2009.03.082 PMID: 19358877

68. Sah P, Faber ESL, Lopez De Armenta M, Power J. The amygdaloid complex: anatomy and physiology. Physiol Rev. 2003; 83: 803–34. https://doi.org/10.1152/physrev.00002.2003 PMID: 12843409

69. Wulsin AC, Solomon MB, Privitera MD, Danzer SC, Herman JP. Hypothalamic-pituitary-adrenocortical axis dysfunction in epilepsy. Physiol Behav. 2016; 166: 22–31. https://doi.org/10.1016/j.physbeh.2016.05.015 PMID: 27195458

70. Lopes MW, Lopes SC, Santos DB, Costa AP, Gonçalves FM, de Mello N, et al. Time course evaluation of behavioral impairments in the pilocarpine model of epilepsy. Epilepsia. 2016; 55: 92–100. https://doi.org/10.1111/epi.13112 PMID: 26773677

71. Müller CJ, Gröticke I, Bankstahl M, Löscher W. Behavioral and cognitive alterations, spontaneous seizures, and neuropathology developing after a pilocarpine-induced status epilepticus in C57BL/6 mice. Exp Neurol. 2009; 219: 284–97. https://doi.org/10.1016/j.expneurol.2009.05.035 PMID: 19500573

72. Gröticke I, Hoffmann K, Löscher W. Behavioral alterations in the pilocarpine model of temporal lobe epilepsy. Exp Neurol. 2007; 207: 329–49. https://doi.org/10.1016/j.expneurol.2007.06.021 PMID: 17714705

73. Steimer T. The biology of fear- and anxiety-related behaviors. Dialogues Clin Neurosci. 2002; 4.

74. Stewart LS, Leung LS. Temporal lobe seizures alter the amplitude and timing of rat behavioral rhythms. Epilepsy Behav. 2003; 4: 153–60. PMID: 12697140

75. de Oliveira CV, Grigoletto J, Funck VR, Ribeiro LR, Royes LFF, Fighiera MR, et al. Evaluation of potential gender-related differences in behavioral and cognitive alterations following pilocarpine-induced status epilepticus in C57BL/6 mice. Physiol Behav. 2015; 142: 143–50. https://doi.org/10.1016/j.physbeh.2015.03.004 PMID: 25749198

76. De Kloet ER, Molendijk ML. Coping with the Forced Swim Stressor: Towards Understanding an Adaptive Mechanism. 2016; 2016.

77. Warden MR, Selimbeyoglu A, Mirzabeikov JJ, Lo M, Thompson KR, Kim S-Y, et al. A prefrontal cortex-brainstem neuronal projection that controls response to behavioural challenge. Nature. 2012; 482: 428–32. https://doi.org/10.1038/nature11167 PMID: 23160494

78. Castro OW, Santos VR, Pun RYK, McKeeen JM, Bate M, Holland KD, et al. Impact of corticosterone treatment on spontaneous seizure frequency and epileptiform activity in mice with chronic epilepsy. PLoS One. 2012; 7: e46044. https://doi.org/10.1371/journal.pone.0046044 PMID: 23029379
79. McCullers DL, Sullivan PG, Scheff SW, Herman JP. Traumatic brain injury regulates adrenocorticosterone receptor mRNA levels in rat hippocampus. Brain Res. 2002; 947: 41–49. https://doi.org/10.1016/S0006-8993(02)02904-9 PMID: 12144851

80. Webb NE, Little B, Loupee-Wilson S, Power EM. Traumatic brain injury and neuro-endocrine disruption: medical and psychosocial rehabilitation. NeuroRehabilitation. 2014; 34: 625–36. https://doi.org/10.3233/NRE-141074 PMID: 24820169

81. Umeoka EHL, Garcia SB, Antunes-Rodrigues J, Elias LLK, Garcia-Cairasco N. Functional characterization of the hypothalamic-pituitary-adrenal axis of the Wistar Audiogenic Rat (WAR) strain. Brain Res. 2011; 1381: 141–7. https://doi.org/10.1016/j.brainres.2011.01.042 PMID: 21256829

82. Sarkisova K, van Luijtelea G. The WAG/Rij strain: a genetic animal model of absence epilepsy with comorbidity of depression [corrected]. Prog Neuropsychopharmacol Biol Psychiatry. 2011; 35: 854–76. https://doi.org/10.1016/j.pnpbp.2010.11.010 PMID: 21093520